India Globalization Capital, Inc. (NYSE: IGC) Anticipates Filing Patents for Portfolio of Drug Candidates in 2018-2019
Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures IGC already has seven provisional filings for phytocannabinoid-based combination therapies Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs India Globalization Capital, Inc. (NYSE American: IGC) anticipates filing, in 2018 and 2019, for international Patent Cooperation Treaty (“PCT”) patents, as well as U.S. national patent filings, for a portfolio of drugs (http://cnw.fm/uc3XT). Its drug for the treatment of Alzheimer’s (IGC-AD1) is anticipated for patent filings in PCT and the U.S. in…